drugset / Trial / NCT02209753
BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis
RandomizedParallel-groupDouble-blindTreatment
Summary
The clinical objective of this study was to determine the effect of BIRB 796 BS on pharmacodynamic markers of psoriasis as a measure of efficacy, to determine the population pharmacokinetics of BIRB 796 BS and to determine the safety of BIRB 796 BS over 4 weeks of treatment in patients with moderate to severe plaque-type psoriasis.
Timeline
- Start
- 2001-06
- Primary completion
- 2002-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIRB 796 BS | Unknown | 5 mg | Oral |
| Subject | BIRB 796 BS | Unknown | 10 mg | Oral |
| Subject | BIRB 796 BS | Unknown | 20 mg | Oral |
| Subject | BIRB 796 BS | Unknown | 30 mg | Oral |